Healthcare / Medical DevicesTaipei Exchange
$15.70
-0.15 (-0.95%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 17%
FCF escenarios
weak_data · normalized FCF $836000.00 · quality 39.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
18/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.1B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-8.6%
↓Gross Margin
13.3%
↓Debt/Equity
0.35
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-19.3%
FCF CAGR
—
FCF margin
0.0%
FCF / Net income
-0.00x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $2.96B · net income $-246.6M · FCF $836000.0
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $2.96B | $2.96B | $4.19B | $4.81B | $5.63B |
| Net Income | $-246.6M | $-246.6M | $629000.00 | $49.1M | $94.1M |
| EBITDA | $-212.5M | $-212.5M | $168.8M | $348.1M | $470.6M |
| EPS | -3.18 | -3.18 | 0.01 | 0.63 | 1.21 |
| Gross Margin | 13.3% | 13.3% | 18.9% | 20.5% | 19.6% |
| Operating Margin | -6.1% | -6.1% | 2.2% | 5.1% | 6.9% |
| Net Margin | -8.3% | -8.3% | 0.0% | 1.0% | 1.7% |
| Balance Sheet | |||||
| Debt/Equity | 0.35 | 0.35 | 0.31 | 0.24 | 0.34 |
| Current Ratio | 2.74 | 2.74 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $836000.00 | $836000.00 | $407.1M | $-191.5M | $-294.0M |
| Returns | |||||
| ROE | -8.6% | -8.6% | 0.0% | 1.8% | 3.3% |
| Valuation | |||||
| P/E | — | — | 2025.00 | 40.40 | 20.37 |
| EV/EBITDA | — | — | 7.45 | 5.13 | 3.15 |
| P/B | 0.42 | 0.42 | 0.56 | 0.73 | 0.67 |
| Growth & Yield | |||||
| Revenue Growth | -29.5% | -29.5% | -12.9% | -14.5% | — |
| EPS Growth | -31900.0% | -31900.0% | -98.4% | -47.9% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-11.8%
Start / end P/E
n/dx → n/dx
EPS bridge
0.01 → -3.18
Residual
-11.8%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.